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Background: Cardiac function is important for patients treated by venovenous extracorporeal membrane
oxygenation (VV ECMO), but data about the effect of VV ECMO on the heart in nonneonates is absent. We studied
the effect of VV ECMO on cardiac performance, cardiomyocyte and mitochondria in an animal model.
Methods: Twelve farm piglets were randomly assigned into two groups: control group and ECMO group. In the
ECMO group, ECMO cannulaes were placed and ECMO was instituted. Hemodynamics was recorded at baseline,
1 hour after induction, and every 4 hours thereafter, to assess the cardiac performance. All animals were monitored
for 24 hours and were euthanized and myocardium was harvested. Myocardial histology, ultrastructure of
cardiomyocyte and mitochondria were observed, and activities of mitochondrial complexes I-V were measured, to
assess the effect to cardiomyocyte and mitochondria.
Results: Hemodynamics were stable in each group of animals throughout the experiment. Interstitial edema,
disorderd and dissolved of focal myofilament, morphological deformations of mitochondria were observed in the
ECMO group. The activities of mitochondrial complexes were decreased in the ECMO group, and complex I and IV
reached significance.
Conclusions: VV ECMO therapy is associated with changes of ultrastructure and function of cardiomyocyte and
mitochondria, inducing myocardium injury. However, the injury was mild and had no effect on the cardiac
performance for healthy piglets.Background
Venovenous extracorporeal membrane oxygenation (VV
ECMO) is a life-saving treatment for severe respiratory
failure patient refractory to conventional therapy. VV
ECMO maintains sufficient tissue oxygenation and carbon
dioxide elimination, so that ventilator settings can be re-
duced which minimizes ventilator-induced lung injury,
and provides time for lung to rest and recovery [1,2]. The
improved survival of patients randomized to the ECMO
arm in the CESAR research [3] and the successful use of
ECMO in the 2009 H1N1 pandemic [4] brought ECMO
into the spotlight of the world, and VV ECMO is coming
into wider use [5]. However, the overall survival of VV* Correspondence: yudrnj@163.com
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reproduction in any medium, provided the orECMO for severe respiratory failure patients was about
50%-60% [6-8], remains for further improvement.
VV ECMO does not provide direct cardiac support,
which depends on intrinsic cardiac function to maintain
cardiac output. In the clinical practice, we found that
there are some patients developing cardiac dysfunction
during VV ECMO therapy, and finally lead to adverse out-
come. Therefore, we postulate that myocardial dysfunction
plays an important role in determining the outcome of
patients treated by VV ECMO, and the possibility of VV
ECMO inducing cardiac injury is important.
Very little is known about the effect of VV ECMO on
the heart, limited to some clinical observations in neo-
nates [9,10], and absent in pediatric and adult populations.
Strleper et al. [9] evaluated the effect of VV ECMO on car-
diac performance by echocardiography in 15 infants, and
found no deleterious effect. Roberts et al. [10] reportedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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But it remains unclear whether VV ECMO has some
potentially adverse effect on the heart, especially for
nonneonatal population.
The aim of the study was to investigate the effect of VV
ECMO on the heart in nonneonatal population. Patients
with severe respiratory failure have a high prevalence of
cardiac dysfunction [11,12]. To avoid the confounding
effect of the disease condition, we performed this study in
a healthy piglet model. Hemodynamics were monitored to
evaluate cardiac performance. As the fundamental of car-
diac function, cardiomyocyte and mitochondria were stud-
ied to find slighter and earlier stage of changes.
Methods
This study was approved by the Animal Care Committee
of Jinling Hospital. All animals received humane care in
accordance with the “Principles of Laboratory Animal
Care” formulated by the Ministry of Health of the People’s
Republic of China.
Animal preparation
Twelve farm piglets of either sex (25–35 kg) were fasted
for 24 hrs. Anesthesia was induced with ketamine
(20 mg/kg), diazepam (8 mg/kg), and atropine (0.1 mg/kg)
intramuscularly, maintained with ketamine (10-20 mg/
kg/hr) and diazepam (8 mg/kg/hr) intravenously. The
animals were intubated through a cervical tracheotomy,
and ventilated on volume-control mode with room air
at a tidal volume setting of 5–8 mL/kg, positive end ex-
piratory pressure of 5 mmHg, and respiratory rate of 15
breaths per minute. Internal jugular vein and femoral
arterial catheters were aseptically placed for intravenous
access, blood pressure monitoring, and sample collec-
tion, pulmonary artery catheter was inserted in the
proximal pulmonary artery via the jugular vein catheter
for monitoring of pulmonary artery pressure (PAP) and
pulmonary artery occlusion pressure (PAOP).
Experimental protocol
After instrumentation and baseline data collection, animals
were randomly assigned into two groups: control group
and ECMO group (n =6/each). In the ECMO group, after a
150 U/kg intravenous bolus of heparin, ECMO cannulaes
(15 F, Medtronic, Minneapolis, Minnesota) were placed in
the superior vena cava through internal jugular vein and
inferior vena cava through femoral vein, and ECMO circu-
lation was instituted. Placement of the cannulaes was con-
firmed via ultrasonograph. Heparin was infused to keep
activated clotting time of 180–220 seconds after insertion.
The ECMO system consisted of a membrane oxygenator
and tubing (Quadrox PLS, Maquet, Rastatt, Germany), a
centrifugal pump (Rotaflow Console, Maquet, Rastatt,
Germany), a heat exchange (Heater-Cooler Unit HCU 30,Maquet, Rastatt, Germany). The circuit was primed with
500 ml hydroxyethyl starch 130/0.4 and 200-300 ml
Ringer’s lactate. Blood in circuit was drained from femoral
vein cannulae and infused into internal jugular vein can-
nulae at a flow rate of 50 ml/(kg.min). 100% oxygen was
given at a flow rate equal to the blood flow rate.
Hemodynamic parameters, including heart rate (HR),
mean arterial pressure (MAP), mean pulmonary artery
pressure (MPAP) and pulmonary artery occlusion pressure
(PAOP) were monitored (PiCCO2, PULSION, Munich,
Germany) and recorded at baseline, 1 hour after induc-
tion, and every 4 hours thereafter until 24 hours. All pres-
sures were determined at end-expiration. Each animal
received lactated Ringer’s solution at a rate of 3 ml/kg/h,
and bolus fluid was provided as required to maintain
MAP above 60 mmHg. The whole volume of fluid intake
of each animal was recorded. Temperature, Serum pH,
glucose and ionized calcium concentration were moni-
tored and maintained normally.
All animals were monitored for 24 hours and were eu-
thanized with a bolus injection of potassium chloride
(40 ml, 0.1 g/ml). Myocardium was harvested immedi-
ately for further measuring.
Myocardial histology examination
Samples from the apex of left ventricular muscle were
fixed and dehydrated with 10% formalin, embedded in
paraffin, cutted into sections, stained with hematoxylin
and eosin (H and E staining), and observed by an optical
microscopy (CX41, Olympus, Tokyo, Japan).
Myocardial ultrastructure examination
Fresh myocardial tissues from the apex of left ventricular
muscle were cut into pieces (1*1*1 mm), fixed with 3%
glutaraldehyde, flushed with phosphate-buffered saline,
fixed with 1% perosmic acid, and dehydrated with acetone.
Ultrathin sections were placed on 200-mesh copper grids
and double stained with 4% uranyl acetate and 0.2% lead
citrate. Sections were examined under transmission elec-
tron microscopy (TEM, JEM-1010, JEOL, Tokyo, Japan).
Ultrastructure of cardiomyocyte and mitochondria was
observed.
The histology and ultrastructure were examined by an
independent pathologist blinded to the grouping.
Mitochondrial isolation and measurement of
mitochondrial complexes activities
Heart tissues from the apex of left ventricular muscle
were put in the ice-cold homogenization buffer. The
mitochondrial pellet was isolated by differential centrifu-
gation [13], and finally resuspended in phosphate buffer.
Mitochondrial protein concentration was determined
using the method of Bradford [14].
Table 1 Time course of hemodynamics in the two groups
Baseline 1 h 5 h 9 h 13 h 17 h 21 h
HR (beats/min)
Control group 136 ± 10.1 130 ± 13.7 126 ± 10.3 123 ± 11.8 124 ± 14.5 128 ± 14.5 131 ± 10.4
ECMO group 134 ± 4.9 140 ± 12.4 130 ± 12.5 133 ± 10.4 128 ± 10.9 124 ± 15.2 128 ± 10.4
MAP (mmHg)
Control group 70 ± 6.5 72 ± 8.5 76 ± 9.3 75 ± 8.5 70 ± 9.1 75 ± 9.9 75 ± 9.3
ECMO group 67 ± 5.0 68 ± 9.5 73 ± 9.4 71 ± 9.1 77 ± 10.6 76 ± 8.5 73 ± 9.9
MPAP (mmHg)
Control group 17.7 ± 4.0 19.2 ± 4.0 18.2 ± 3.3 19.0 ± 3.6 18.8 ± 3.9 16.7 ± 4.0 18.3 ± 4.0
ECMO group 18.5 ± 3.1 20.2 ± 4.4 19.5 ± 4.5 20.2 ± 4.6 19.3 ± 4.0 19.0 ± 3.1 18.7 ± 3.6
PAOP (mmHg)
Control group 12.0 ± 2.1 11.7 ± 1.2 11.3 ± 1.9 11.0 ± 0.9 11.2 ± 1.2 11.7 ± 1.9 11.5 ± 1.2
ECMO group 11.2 ± 1.5 11.0 ± 1.1 11.8 ± 1.2 12.0 ± 0.9 12.0 ± 1.7 11.8 ± 1.6 12.0 ± 1.4
Data are shown as mean ± SD. No significance was presented. HR heart rate, MAP mean arterial pressure, MPAP mean pulmonary artery pressure, PAOP pulmonary
artery occlusion pressure.
Figure 1 Volume of fluid intake of each group. Data are shown
as mean ± SD. *P <0.05 vs. control group.
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plexes I-V were measured using spectrophotometry [15].
The activity of complex I was expressed as μmoles of
nicotinamide adenine dinucleotide reduced (NADH) ox-
idized/min/mg protein, the activity of complex II was
expressed as μmoles of 2,6-diclorophenol indophenol
(DCIP) oxidized/min/mg protein, the activity of complex
III was expressed as μmoles of decylubiquinol oxidized/
min/mg protein, the activity of complex IV was expressed
as μmoles of cytochrome c oxidized/min/mg protein, the
activity of complex V was expressed as μmoles of NADH
oxidized/min/mg protein.
Statistical analysis
All the statistical analyses of the data were performed by
the SPSS 17.0 software (SPSS Inc., Chicago, Illinois).
Data are expressed as mean ± SD or median (interquartile
range). Data were statistically analyzed using one-way ana-
lysis of variance (ANOVA). Significant results were post
hoc analyzed, using the least significance difference (LSD)
tests. Statistical significance was established as p <0 .05.
Results
There was no difference in body weight and other char-
acteristic between groups.
Hemodynamics and fluid intake
Hemodynamic parameters, including heart rate (HR),
mean arterial pressure (MAP), mean pulmonary artery
pressure (MPAP) and pulmonary artery occlusion pressure
(PAOP) were stable in each group of animals throughout
the experiment, and no significance was presented be-
tween groups (Table 1). However, fluid intake in the
ECMO group was significantly more than the control
group (Figure 1).Myocardial histology and ultrastructure changes
H and E staining in the control group showed that
cardiomyocytes were arranged in rows, the fiber struc-
ture of cardiomyocyte was clear. There was no obvious
damage to myocardial fibers in the ECMO group, but
interstitial edema was observed, myocardial fiber spacing
was increased (Figure 2).
Under TEM, samples from the control group showed
myofilament was ordered, the structure was clear, the
sarcolemma was intact. Samples from the ECMO group
showed myofilament was mildly disorderd, dissolved of
focal myofilament can be observed (Figure 3).
Figure 2 Histology of myocardial with H and E staining under optical microscopy (magnification*400). Myocardial structure was normal
in either group, but interstitial edema was observed in the ECMO group.
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The mitochondria from the control group exhibited well-
defined double membranes with normal cristae arrange-
ment Abnormal mitochondria can be observed in the
ECMO, characterized by mitochondrial swollen, decreased
density of inner membrane cristae, along with vacuolation,
but the outer membrane was integrated (Figure 4).
The activities of mitochondrial complexes were de-
creased in the ECMO group versus the control group
(Figure 5), and activities of complex I and IV reached
significance.
Discussion
As a lifesaving treatment, VV ECMO is becoming more
and more essential for children and adults with refrac-
tory respiratory failure, and such patients have a high
prevalence of cardiac dysfunction [11,12]. VV ECMO
does not provide direct cardiac support, which depends
on intrinsic cardiac function to maintain cardiac output.
Therefore, the condition of cardiac function during VVFigure 3 Ultrastructure of cardiomyocyte under TEM (magnification*8
group, and mildly disorderd of myofilament and dissolved of focal myofilamECMO is closely associated with the outcome. We
present the first detailed laboratory investigation in the
effect of VV ECMO on the heart in nonneonatal
population.
In this study, the volume of fluid intake was significantly
more in the ECMO group. Golej et al. [16] found MAP
decreased at the initiation of VV ECMO and increased in
a short time. In consideration of the numerous influence
factors, we haven`t analyzed the immediate hemodynamic
response. But we have observed similar MAP fluctuation
at the initiation of VV ECMO and restored quickly after
fluid bolus, which contributed a lot to the amount of the
fluid taken in the ECMO group, and may associated with
myocardium interstitial edema.
In addition, the ECMO group disorderd and dissolved
of focal myofilament, morphological deformations of
mitochondria and decreased activities of mitochondrial
complexes compared with the control group, suggesting
that VV ECMO therapy is associated with myocardium
injury.000). Ultrastructure of cardiomyocyte was normal in the control
ent (pointed by arrow) were observed in the ECMO group.
Figure 4 Ultrastructure of mitochondria under TEM (magnification*20000). The mitochondria was normal in the control group;
morphological deformations characterized by mitochondrial swollen, decreased density of inner membrane cristae, along with vacuolation
(pointed by arrow) were observed in the ECMO group.
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research. Several factors may contribute to it, such as
activation of systemic inflammatory response, increase
of reactice oxygen species (ROS), and release of toxic
substances by ECMO.
The instigation of a systemic inflammatory state with
exposure to ECMO is well accepted [17-21]. Fortenberry
et al. [19] found that neutrophil was activated and con-
centration of circulating interleukin (IL)-8 increased sig-
nificantly after ECMO initiation. Adrian et al. [20]Figure 5 Enzymatic activities of mitochondrial complex I-V in left ven
median, interquartile range, 10th and 90th percentile. *P <0.05 vs. control g
min/mg protein, complex II-μmoles of DCIP oxidized/min/mg protein, com
IV- μmoles of cytochrome c oxidized/min/mg protein, complex V -μmolesperfused blood in vitro ECMO circuit performed for
24 hours, and found cytokines, including IL-1β, IL-1
receptor antagonist, IL-8, IL-6, tumor necrosis factor α
(TNF-α) were increased. Mu et al. [21] found concentra-
tions of circulating IL-6 and IL-10 increased significantly
in a hemorrhage-reperfusion piglet model on modern
ECMO. The inflammatory cytokines have been impli-
cated in mediating myocardial injury [22-24]. Deng et al.
[25] and Hennein et al. [26] found that preoperative left
ventricular dysfunction is associated with the degree oftricular myocardium in each groups of animals. Box plots indicate
roup. Units are expressed as: complex I-μmoles of NADH oxidized/
plex III-μmoles of decylubiquinol oxidized/min/mg protein, complex
of NADH oxidized/min/mg protein.
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found that cardiac dysfunction occurred after cardiopul-
monary bypass was associated with the increase of sys-
temic and myocardial TNF-α, and anti-inflammatory
pretreatment with methylprednisolone abolished the in-
crease of TNF-α attenuated myocardial dysfunction.
It is well established that cardiopulmonary bypass is
associated with increased production of reactice oxygen
species (ROS) [28,29], and similar results were verified
during ECMO therapy. Hirthler et al. [17] and Underwood
et al. [18] detected that systemic free radical was increased
during ECMO. Moller et al. [30] found free oxygen radical
scavenging enzymes such as superoxide dismutase and
glutathione reductase were decreased during ECMO in
healthy lambs, resulted in increased lipoperoxide level.
ROS are central mediators of cardiac injury, especially for
mitochondria, and finally resulting in cardiac dysfunction
[31]. Precious researches indicate that lacking of ROS
scavenging enzyme aggravate myocardial injury [32], and
antioxidant potentiate cardiac protection [33].
In addition, it is not clear whether the ECMO circuit
adds some toxic substances such as endotoxin [17] and
plasticizers [34] impact the myocardium.
Despite changes of ultrastructure and function of
cardiomyocyte and mitochondria induced by VV ECMO,
we found hemodynamics during VV ECMO therapy was
stable, suggesting that the injury was mild, and had no
effect on the cardiac performance for healthy piglets, con-
sistently with the results of Strieper [9] and Roberts [10].
However, energy is the base to maintain normal cardiac
pump function, continuously produced by mitochondrial
respiration [35]. Therefore, any alteration of mitochondrial
structure and function are fundamental for cardiac func-
tion. The changes of mitochondria in this study do not
impact the cardiac performance, but may impact the car-
diac reserved function, which may essential for a margin-
ally functional heart or when cardiac demand increased
under disease conditions.
Furthermore, under disease conditions with severe
hypoxia, hypoxia itself plays an important role in myo-
cardial injury [12], and the advantage of VV ECMO in
providing adequate oxygenation to the myocardium may
be of protective effect. Shen et al. [36] found cardiac
dysfunction due to hypoxia coronary perfusion during
venoarterial ECMO in a hypoxemic swine model, postulat-
ing that VV ECMO may be more adequate for hypoxemic
condition. However, abrupt hyperoxia for a hypoxemic
heart may induce reoxygenation injury, causing further
cardiac injury. Allen et al. [37] and Trittenwein et al. [38]
found increased amounts of oxygen free radicals after
reoxygenation on cardiopulmonary bypass and ECMO
respectively.
Therefore, the effect of VV ECMO on the myocardium
and cardiac performance would be more complicated forpatients under hypoxemic condition, and should be fur-
ther investigated. However, we present the potentially
adverse effect of VV ECMO alone on the heart for the
first time, calling for attention to the impact on heart
during VV ECMO, and provide a potentially aspect to
improve the survival of VV ECMO.
Conclusions
In conclusion, the results of our study showed that VV
ECMO is associated with changes of ultrastructure and
function of cardiomyocyte and mitochondria, inducing
myocardium injury. The underlying mechanisms should
be further investigated. However, the injury was mild
and had no effect on the cardiac performance for healthy
piglets.
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